Table 1 Characteristics of patients with myelodysplastic syndrome receiving transplantation

Patient age, years

48 (19–66)

46 (23–64)

0.637

Patient sex, male/female

67/52

22/12

0.381

Bone marrow blasts

  < 5%

26 (21.8%)

6 (17.6%)

0.595

  ≥ 5%

93 (78.2%)

28 (82.4%)

MDS subentities

 MDS-LB/h

26

6

NA

 MDS-IB1/2

57

0

 MDS-f

36

28

MDS-biTP53, Yes/No

9/110

4/30

0.438

Cytogenetics

 Good/very good

61 (51.3%)

19 (55.9%)

0.893

 Intermediate

31 (26.1%)

8 (23.5%)

 Poor/very poor

27 (22.7%)

7 (20.6%)

IPSS-R

 Low/Intermediate

34 (28.6%)

9 (26.5%)

0.810

 High/Very high

85 (71.4%)

25 (73.5%)

IPSS-M

 Low/Moderate low

15 (12.6%)

2 (5.9%)

0.485

 High/Moderate high

57 (47.9%)

16 (47.1%)

 Very high

47 (39.5%)

16 (47.1%)

Pre-HSCT Chemotherapy

 HMAs only

49 (41.2%)

14 (41.2%)

0.603

 HMAs + VEN

13 (10.9%)

4 (11.8%)

 HMAs + chemotherapy

21 (17.6%)

3 (8.8%)

 Other

36 (30.3%)

13 (38.2%)

Refined DRI

 Intermediate

58 (48.7%)

20 (58.8%)

0.300

 High

61 (51.3%)

14 (41.2%)

Donor age, years

32 (12 – 55)

30 (15 – 59)

0.799

Donor sex, male / female

78 / 41

23 / 11

0.820

Donor type

 HID

80 (67.2%)

22 (64.7%)

0.725

 MSD

21 (17.6%)

5 (14.7%)

 URD

18 (15.1%)

7 (20.6%)

ABO blood type

 Compatible

59 (49.6%)

21 (61.8%)

0.313

 Major/bidirectional

33 (27.7%)

9 (26.5%)

 Minor

27 (22.7%)

4 (11.8%)

Conditioning regimen

 RIC

35 (29.4%)

11 (32.4%)

0.742

 MAC

84 (70.6%)

23 (67.6%)

ATG

 ATG-G

75 (63.0%)

20 (58.8%)

0.872

 ATG-F

33 (27.7%)

10 (29.4%)

 None

11 (9.2%)

4 (11.8%)

MNCs (10⁸/kg)

11.4 (4.4–39.0)

11.8 (6.3–31.3)

0.649

CD34⁺ cells (10⁶/kg)

5.3 (1.2–14.3)

5.6 (2.1–22.5)

0.417